Section 8: Clinical Vignettes (Part II)

Vignette 3: Bipolar + Alcohol Use: When the Mood Stabilizer Choice Matters

Presentation: Daniel, age 42, has Bipolar II disorder with a 15-year history of alcohol use disorder. He was recently hospitalized for a severe depressive episode with suicidal ideation. He reports drinking 6-8 beers nightly "to stop my mind from racing" and to help him sleep. He has been prescribed lamotrigine 200 mg but is not taking it consistently. He has two prior suicide attempts, both during depressive episodes while intoxicated. He presents now for outpatient follow-up 5 days after discharge.

Clinical reasoning: Daniel represents the prototypical tri-morbid loop (Section 3.2): bipolar depression, alcohol use disorder, and elevated suicide risk, each amplifying the others. His belief that alcohol helps his racing thoughts illustrates the self-medication hypothesis (Section 2.2), but the Sperry et al. (2024) data demonstrates that alcohol is a forward destabilizer of bipolar mood, particularly for BD-II hypomanic symptoms (Section 2.3). His two prior attempts during depressive episodes while intoxicated place him at extremely high risk (Section 5.3: prior attempts yield HR 4.10 for completed suicide; comorbid SUD is the most potent suicide risk amplifier). This is also the highest-risk transition period: he is within the first week post-discharge, when suicide rates are up to 300 times the population rate (Section 5.6).

Management approach: (1) Immediate safety assessment using C-SSRS (Columbia Suicide Severity Rating Scale, a standardized tool for assessing the severity and immediacy of suicidal ideation and behavior); update safety plan specific to his current depressive state (Section 5.5: low-barrier coping strategies, third-party means restriction). (2) The lithium vs. valproate question is clinically significant: while lithium's anti-suicidal properties are a strong argument given his two prior attempts (Section 5.4: OR 0.13 for completed suicide), active alcohol use is a negative predictor of lithium response, and lithium's narrow therapeutic index (the gap between the dose that works and the dose that becomes toxic) is dangerous with inconsistent medication-taking and the dehydration associated with heavy drinking (Section 2.4). Valproate has specific evidence for reducing alcohol consumption in comorbid bipolar-AUD populations (Section 2.4: significantly fewer heavy drinking days, p = .02). However, at age 42, the 2024 NICE restrictions (UK guidelines) on new valproate prescriptions for patients under 55 create a regulatory barrier in jurisdictions that follow NICE. Note: the US FDA has separate but overlapping warnings, including boxed warnings for pregnancy but not an age-based general restriction for males; US clinicians should follow their applicable regulatory framework while considering the reproductive safety data. An atypical antipsychotic with broad-spectrum efficacy, such as quetiapine, may be the most practical first-line option. (3) Integrated treatment is strongly recommended by all major guidelines (Section 2.4: pooled RR 1.71 for adverse outcomes in siloed treatment). Refer for Integrated Group Therapy. (4) Provide direct psychoeducation about the Sperry data: alcohol is not helping his mood, it is actively destabilizing it, and the improvement from stopping may be substantial. (5) Schedule rapid follow-up within 48-72 hours given the post-discharge risk period.

Vignette 4: Diagnostic Bias: The Misdiagnosed Patient

Presentation: Terrence, age 24, African American, presents to your clinic with a new patient intake. He carries a diagnosis of "paranoid schizophrenia" assigned at age 19 during his first psychiatric hospitalization, where he presented with auditory hallucinations (voices commenting on his behavior), paranoid ideation, and disorganized speech. He has been on paliperidone long-acting injectable for five years. His mother, who accompanies him, states: "He's not the same person he was in high school. He was so bright and social. Then every spring and fall, he'd get these episodes where he wouldn't sleep for days, thought he was going to be famous, spent thousands of dollars, and then crashed into the worst depression. The voices only happened during the high periods." She adds that his maternal uncle has bipolar disorder.

Clinical reasoning: This presentation should raise immediate concern for diagnostic bias (Section 7.1: Strakowski et al., 2003). His mother's description of episodic mood elevation (decreased sleep, grandiosity, spending sprees) alternating with severe depression, with psychotic features occurring exclusively during mood elevation, is the hallmark of Bipolar I disorder with psychotic features, not schizophrenia. In schizophrenia, psychotic symptoms persist independently of mood state. His family history of bipolar disorder further supports this. The Strakowski data shows that African American men with affective disorders are significantly more likely to be misdiagnosed with schizophrenia (p < .03), and the diagnostic disagreement rate is higher for Black patients (Section 7.1). His five years on a long-acting injectable antipsychotic without mood stabilization means five years of uncontrolled affective cycling, unrecognized depressive episodes, and missed suicide risk.

Management approach: (1) Obtain detailed collateral history from his mother mapping the chronological relationship between mood episodes and psychotic symptoms. (2) Use a structured diagnostic interview to re-evaluate the diagnosis. (3) If the psychotic symptoms are confined to mood elevation episodes, the diagnosis is Bipolar I with psychotic features. (4) Initiate a mood stabilizer (lithium has the strongest anti-suicidal evidence and is first-line for BD-I maintenance; Section 5.4). (5) Collaborate with psychiatry to carefully cross-taper from the LAI antipsychotic, which was treating the psychosis but not the underlying mood disorder. (6) Document the diagnostic revision transparently and educate the patient and family about the corrected diagnosis and its treatment implications.

Key Takeaways for Clinical Practice

1. Chronic irritability in children is not mania. The 40-fold increase in pediatric bipolar diagnoses between the 1990s and 2000s was driven by misclassifying chronic, non-episodic irritability as a developmental form of mania. Longitudinal evidence definitively shows that this presentation (now classified as DMDD) predicts future unipolar depression, not bipolar disorder. True pediatric bipolar disorder requires distinct episodic mood elevation with associated manic criteria and is primarily a disease of adolescence.

2. Substance use is the most common comorbidity in bipolar disorder, affecting over half of all patients. Alcohol is a pharmacological destabilizer of bipolar mood, not merely a coping response. Cannabis worsens mania and psychosis longitudinally despite patients' subjective belief that it helps. Integrated treatment (single team, concurrent care) is the standard; sequential models ("get sober first") produce worse outcomes.

3. For comorbid anxiety, stabilize mood first. Approximately half of bipolar patients will have a comorbid anxiety disorder. Adjunctive SSRI use with mood stabilizer coverage is safer than historically feared (2024 target trial emulation showed no significant manic switching risk), but efficacy is modest. Benzodiazepines should be limited to short-term bridging. Intensive psychotherapy (CBT, family-focused therapy, or IPSRT) is safe and effective, with NNTs as low as 3.22 for recovery in bipolar patients with comorbid anxiety in the STEP-BD intensive arm, though this reflects treatment allocation by patient choice rather than randomization (Simon et al., 2004, STEP-BD data).

4. Stimulants can be safely used in bipolar patients with genuine ADHD, but only after mood stabilization. All major guidelines strongly recommend a hierarchical approach: stabilize mood first, then address persistent ADHD symptoms during euthymia. With mood stabilizer coverage, stimulants carry no increased manic switching risk in registry data. Methylphenidate may carry lower psychosis risk than amphetamines.

5. For therapists and school psychologists: Your role with comorbid bipolar patients includes recognizing early warning signs of mood episodes, supporting medication adherence through psychoeducation, providing evidence-based psychotherapy (CBT, DBT skills for mixed state distress tolerance, IGT for substance use comorbidity), and advocating for school accommodations that address both psychiatric symptoms and medication side effects. If a patient's anxiety, ADHD symptoms, or substance use seems treatment-resistant, screen for unrecognized bipolar disorder.

6. Bipolar disorder carries the highest suicide risk of any psychiatric diagnosis. Mixed states are the most dangerous period (OR 9.0 for suicide death). Lithium has a unique anti-suicidal effect (OR 0.13 for completed suicide vs. placebo, with a wide CI reflecting the rarity of suicide events but consistent direction of benefit) that should explicitly influence treatment selection when suicide risk is elevated. Safety plans must be mood-state-specific: depression plans need low-barrier strategies for anergia; mixed state plans need intense distress tolerance techniques and lowered escalation thresholds; mania plans must empower collateral supports because the patient will lose insight.

7. Do not discontinue mood stabilizers upon discovering pregnancy. The relapse rate without medication is 70-80%, and the consequences for mother and fetus are severe. Lithium's cardiac risk has been recalibrated: approximately 0.6-0.7% absolute risk for Ebstein's anomaly, dose-dependent and much lower than the 3-4% historically cited. Lamotrigine is the safest mood stabilizer in pregnancy but requires aggressive dose adjustments as clearance increases up to 275%. Valproate is absolutely contraindicated.

8. Plan for postpartum psychosis proactively in high-risk bipolar women. Women with bipolar disorder who have a history of postpartum psychosis, chronic bipolar disorder with prior peripartum episodes, or a strong family history of postpartum psychosis face a 20-25% risk. Immediate postpartum lithium prophylaxis reduces this to approximately 10% (NNT of 3 from meta-analytic data). The plan must be in place before delivery: medication orders, sleep preservation strategy, family education about warning signs (confusion, disorganized behavior, paranoia, beliefs about the infant that seem bizarre). Distinguish postpartum psychosis (ego-syntonic delusions, absent reality testing, risk of infanticide) from perinatal OCD (ego-dystonic intrusive thoughts, intact reality testing, essentially zero risk of acting).

9. Actively mitigate diagnostic bias. Black patients are systematically under-diagnosed with bipolar disorder and over-diagnosed with schizophrenia. When evaluating any patient with psychotic features, map the chronological relationship between psychosis and mood symptoms. If psychosis resolves with mood normalization, the diagnosis is likely bipolar with psychotic features, not schizophrenia. Implicit bias training and structured diagnostic tools are essential safeguards.

10. The days immediately following psychiatric discharge are the highest-risk period for suicide. Suicide rates are up to 300 times higher in the first post-discharge week. Schedule the first outpatient appointment within 48-72 hours. Verify medication adherence, especially lithium (abrupt discontinuation triggers severe rebound risk). Active contact strategies (outreach calls, peer support) during the gap days save lives.

Key References

Starred (★) papers are recommended for clinicians who want to read further.

**★ **Moreno, C., Laje, G., Blanco, C., et al. (2007). National trends in the outpatient diagnosis and treatment of bipolar disorder in youth. Archives of General Psychiatry, 64(9), 1032-1039.

**★ **Viguera, A.C., Whitfield, T., Baldessarini, R.J., et al. (2007). Risk of recurrence in women with bipolar disorder during pregnancy: prospective study of mood stabilizer discontinuation. American Journal of Psychiatry, 164(12), 1817-1824.

**★ **Patorno, E., Huybrechts, K.F., Bateman, B.T., et al. (2017). Lithium use in pregnancy and the risk of cardiac malformations. New England Journal of Medicine, 376(23), 2245-2254.

**★ **Cipriani, A., Hawton, K., Stockton, S., Geddes, J.R. (2013). Lithium in the prevention of suicide in mood disorders: updated systematic review and meta-analysis. BMJ, 346, f3646.

**★ **Schaffer, A., Isometsä, E.T., Tondo, L., et al. (2015). International Society for Bipolar Disorders Task Force on Suicide: meta-analyses and meta-regression of correlates of suicide attempts and suicide deaths in bipolar disorder. Bipolar Disorders, 17(1), 1-16.

**★ **Bergink, V., Bouvy, P.F., Vervoort, J.S.P., et al. (2012). Prevention of postpartum psychosis and mania in women at high risk. American Journal of Psychiatry, 169(6), 609-615.

**★ **Strakowski, S.M., Keck, P.E., Arnold, L.M., et al. (2003). Ethnicity and diagnosis in patients with affective disorders. Journal of Clinical Psychiatry, 64(7), 747-754.

**★ **Sperry, S.H., Stromberg, A.R., Murphy, V.A., et al. (2024). Longitudinal interplay between alcohol use, mood, and functioning in bipolar spectrum disorders. JAMA Network Open, 7(6), e2415295.

**★ **Viktorin, A., Rydén, E., Thase, M.E., et al. (2017). The risk of treatment-emergent mania with methylphenidate in bipolar disorder. American Journal of Psychiatry, 174(4), 341-348.

Scheffer, R.E., Kowatch, R.A., Carmody, T., Rush, A.J. (2005). Randomized, placebo-controlled trial of mixed amphetamine salts for symptoms of comorbid ADHD in pediatric bipolar disorder after mood stabilization with divalproex sodium. American Journal of Psychiatry, 162(1), 58-64.

**★ **Rohde, C., Østergaard, S.D., Jefsen, O.H. (2024). A nationwide target trial emulation assessing the risk of antidepressant-induced mania among patients with bipolar depression. American Journal of Psychiatry, 181(7), 630-638.

Baldessarini, R.J., Tondo, L. (2003). Suicide risk and treatments for patients with bipolar disorder. JAMA, 290(11), 1517-1519.

Dong, M., Lu, L., Zhang, L., et al. (2018). Prevalence of suicide attempts in bipolar disorder: a systematic review and meta-analysis of observational studies. Epidemiology and Psychiatric Sciences, 29, e63.

Schiweck, C., Arteaga-Henríquez, G., Aichholzer, M., et al. (2021). Comorbidity of ADHD and adult bipolar disorder: a systematic review and meta-analysis. Neuroscience and Biobehavioral Reviews, 124, 100-123.

Leibenluft, E. (2003). Defining clinical phenotypes of juvenile mania. American Journal of Psychiatry, 160(3), 430-437.

Brotman, M.A., Schmajuk, M., Rich, B.A., et al. (2006). Prevalence, clinical correlates, and longitudinal course of severe mood dysregulation in children. Biological Psychiatry, 60(9), 991-997.

Geller, B., Luby, J.L., Joshi, P., et al. (2012). A randomized controlled trial of risperidone, lithium, or divalproex sodium for initial treatment of bipolar I disorder, manic or mixed phase, in children and adolescents. Archives of General Psychiatry, 69(5), 515-528.

Molenaar, N.M., Lambregtse-van den Berg, M.P., Bergink, V. (2021). Management of lithium dosing around delivery: an observational study. Bipolar Disorders, 23(3), 304-306.

**★ **Meador, K.J., Baker, G.A., Browning, N., et al. (2009). Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs. New England Journal of Medicine, 360(16), 1597-1605.

Clark, C.T., Klein, A.M., Perel, J.M., et al. (2013). Lamotrigine dosing for pregnant patients with bipolar disorder. American Journal of Psychiatry, 170(11), 1240-1247.

Park, Y., Hernández-Díaz, S., Bateman, B.T., et al. (2018). Continuation of atypical antipsychotic medication during early pregnancy and the risk of gestational diabetes. American Journal of Psychiatry, 175(6), 564-574.

Wesseloo, R., Kamperman, A.M., Munk-Olsen, T., et al. (2016). Risk of postpartum relapse in bipolar disorder and postpartum psychosis: a systematic review and meta-analysis. American Journal of Psychiatry, 173(2), 117-127.

Biederman, J., DiSalvo, M., Fried, R., Woodworth, K.Y., Biederman, I., Faraone, S.V. (2019). Quantifying the protective effects of stimulants on functional outcomes in attention-deficit/hyperactivity disorder: a focus on number needed to treat statistic and sex effects. Journal of Adolescent Health, 65(6), 784-789.

Benarous, X., et al. (2025). Prevalence and comorbidity rates of disruptive mood dysregulation disorder in epidemiological and clinical samples: systematic review and meta-analysis. European Psychiatry, 68(1), e18.

Zhang, Y., et al. (2024). Systematic review and meta-analysis: pharmacological and nonpharmacological interventions for disruptive mood dysregulation disorder. Journal of Child and Adolescent Psychopharmacology, 34(5), 217-225.

Salazar de Pablo, G., et al. (2025). Occurrence of psychosis and bipolar disorder in individuals with ADHD treated with stimulants: a systematic review and meta-analysis. JAMA Psychiatry, 82(7), 718-728.

Findling, R.L., Short, E.J., McNamara, N.K., et al. (2007). Methylphenidate in the treatment of children and adolescents with bipolar disorder and attention-deficit/hyperactivity disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 46(11), 1445-1453.

Miskowiak, K.W., et al. (2024). The effect of ADHD medication on cognitive impairment in bipolar disorder: ISBD Targeting Cognition Task Force systematic review. Bipolar Disorders, 26(4), 332-348.

Pennell, P.B., Peng, L., Newport, D.J., et al. (2008). Lamotrigine in pregnancy: clearance, therapeutic drug monitoring, and seizure frequency. Neurology, 70(22 Pt 2), 2130-2136.

James, A., Hoang, U., Seagroatt, V., et al. (2014). A comparison of American and English hospital discharge rates for pediatric bipolar disorder, 2000-2010. Journal of the American Academy of Child and Adolescent Psychiatry, 53(6), 614-624.

Viguera, A.C., Nonacs, R., Cohen, L.S., et al. (2000). Risk of recurrence of bipolar disorder in pregnant and nonpregnant women after discontinuing lithium maintenance. American Journal of Psychiatry, 157(2), 179-184.

Christensen, J., Grønborg, T.K., Sørensen, M.J., et al. (2013). Prenatal valproate exposure and risk of autism spectrum disorders and childhood autism. JAMA, 309(16), 1696-1703.

PsychHQ

Clinical Vignettes: SUD, Diagnostic Bias & Key Takeaways